Results 131 to 140 of about 6,740 (170)

Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapy. [PDF]

open access: yesNucleic Acids Res
Rajendra E   +26 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

PARG Inhibitors and Functional PARG Inhibition Models

Current Protein & Peptide Science, 2016
Poly(ADP-ribose) polymerases (PARPs) family proteins catalyze poly(ADP-ribosylation) (PARylation) by conjugating ADP-ribose residues repeatedly on amino acid residues using nicotinamide adenine dinucleotide as a substrate. The inhibitors of PARP widely block DNA repair processes and are currently examined in clinical trials of cancer therapy.
Yuka, Sasaki   +6 more
openaire   +2 more sources

Purification of Recombinant Human PARG and Activity Assays

2022
The purification of poly(ADP-ribose) glycohydrolase (PARG) from overexpressing bacteria Escherichia coli is described here as a fast and reproducible one chromatographic step protocol. After cell lysis, GST-PARG-fusion proteins from the crude extract are affinity purified by a glutathione 4B sepharose chromatographic step.
Amé, Jean-Christophe   +1 more
openaire   +3 more sources

Plant PARPs, PARGs and PARP-like Proteins

Current Protein & Peptide Science, 2016
Poly(ADP-ribos)ylation, originally described as a mechanism of DNA break repair, is now considered as part of a complex regulatory system involved in dynamic reorganization of chromatin structure, transcriptional control of gene expression and regulation of metabolism. In plants poly(ADP-ribos)ylation has received surprisingly little attention.
Julia P, Vainonen   +3 more
openaire   +2 more sources

PARP and PARG as novel therapeutic targets

Drugs of the Future, 2002
Poly(ADP-ribose) is synthesized by poly(ADP-ribose) polymerase (PARP) from β-nicotinamide adenine dinucleotide (NAD + ). It is mainly degraded by poly(ADP-ribose) glycohydrolase (PARG). The expanding family of PARP currently consists of PARP 1 - 3 , vPARP, Tankyrase 1 - 2 , 2 , and more members are being characterized.
null Zhang, J., null Li, J.-H.
openaire   +1 more source

Targeting PARG in HCC

Nature Reviews Gastroenterology & Hepatology, 2022
openaire   +2 more sources

INHIBITORS OF PARG

2023
CHANG PAUL   +2 more
openaire   +5 more sources

Home - About - Disclaimer - Privacy